In Vivo Gene Editing CAR-T Platform-BRL Medicine

Cell TherapyAllogeneic Universal Cell Platform

Universal Cell Platform refers to the use of gene editing technology to transform allogeneic immune cells to eliminate immune rejection.
lEARN MORE
Cell TherapyNon-viral site-specific integration CAR-T platform

Non-viral site-specific integration CAR-T platform has several advantages, including simplified manufacturing process, shortened preparation time, higher product uniformity...
lEARN MORE Non-viral site-specific integration CAR-T platform
Cell TherapyEnhanced T Cell Platform

Enhanced T cell Platform including HyperCART ^® , are mainly to solve the global highlighted problem in solid tumor therapy through genetic modification of T cells.
lEARN MORE
Cell TherapyIn Vivo Gene Editing CAR-T Platform

The in vivo CAR-T platform represents an innovative approach that enables direct in vivo delivery of chimeric antigen receptor (CAR) genes into a patient’s T cells, thereby generating functional CAR-T cells internally.
lEARN MORE In vivo CAR-T

In Vivo Gene Editing CAR-T Platform

The in vivo CAR-T platform represents an innovative approach that enables direct in vivo delivery of chimeric antigen receptor (CAR) genes into a patient’s T cells, thereby generating functional CAR-T cells internally. Specifically, viral or non viral vectors are used to specifically deliver the gene fragment encoding car to T cells, which can achieve rapid, instantaneous and controllable therapeutic effect without going through the complex process of traditional in vitro separation and expansion of T cells. This platform has the core advantages of greatly simplifying the process, significantly reducing the production cost and greatly improving the accessibility. It provides a new technical path and solution for tumor and autoimmune diseases.

The development of the era of gene therapy

In 2024, Science magazine announced CAR-T therapy for autoimmune diseases as “Breakthrough of the Year”.

In 2023, FUCASO, the world's first all human targeted BCMA CAR-T therapy (Equecabtagene Autoleucel) was approved for marketing by the Chinese NMPA for the treatment of recurrent or refractory multiple myeloma (R/R MM).

In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of R/R MM in China, was approved by the FDA for marketing.

In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry

In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia

In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA

In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)

In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (R/R ALL)

In 2016, the first generation of single-base editors were developed

In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced

In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)

In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced

In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)

In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced

In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)

About Us: About Us; Leadership; Our Culture; News; Contact Us

Gene Therapy: Gene Editing Technology Innovation Platform; Hematopoietic Stem Cell Platform

Cell Therapy: Allogeneic Universal Cell Platform; Non-viral site-specific integration CAR-T platform; Enhanced T Cell Platform; In Vivo Gene Editing CAR-T Platform

Contact Us: Tel： 021-64340008; Email： info@brlmed.com; Address： Science&Technology Park, 3699 Yuanjiang Road, Minhang District, Shanghai

简体中文

English

Cell TherapyAllogeneic Universal Cell Platform

Cell TherapyNon-viral site-specific integration CAR-T platform

Cell TherapyEnhanced T Cell Platform

Cell TherapyIn Vivo Gene Editing CAR-T Platform

In Vivo Gene Editing CAR-T Platform

The development of the era of gene therapy